Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last Hour:
Last 24 Hours:

Amryt Pharma hails phase III success for skin gel as "significant milestone"

% of readers think this story is Fact. Add your two cents.

Amryt Pharma PLC (NASDAQ:AMYT; LON:AMYT) hailed as a “significant milestone” the phase III success of FILSUVEZ, a gel for a rare and extremely painful skin condition called epidermolysis bullosa (EB).

The study achieved its main goal, known in the scientific parlance as the primary endpoint, of accelerating the wound healing process

The next step is a rolling submission programme to the regulatory authorities, with the company applying for speedy approval in both the US and EU.

It previously received fast track designation and rare paediatric disease designation from America’s Food & Drug Administration, and it expects to be eligible to apply for a rare paediatric disease priority review voucher.

Submissions to the US and EU regulators are expected to be made late in the first quarter of next year.

The full set of data will be fully assessed and presented to an upcoming scientific symposium, Amryt said.

In all 223 people were enrolled onto the phase III EASE trial, 156 of them children or infants.

It was a double-blind study in which one group received the active treatment while the other didn’t. Only at the end did doctors know which group was which.

The Amryt team then compared total wound closer over 45 days of treatment across the two groups. The results were highly statistically significant.

Chief executive, Dr Joe Wiley, said: “We are proud to present these positive and encouraging results, demonstrating that FILSUVEZ could make an important difference to the lives of patients.

“We would like to extend our gratitude to all of the patients, their families, carers and physicians for their participation in the EASE trial and we look forward to working with regulatory authorities to make FILSUVEZ available as the first approved therapeutic treatment for EB patients.

“All of the team at Amryt are very excited by today’s news and the impact this may have in our efforts to help patients with this very distressing condition.”

EB is a rare, chronic and distressing genetic skin disorder that causes the skin layers and internal body linings to separate.

Amryt estimates there are as many as 30,000 youngsters and adults affected by it in the US and there are 500,000 sufferers worldwide.

The potential market for FILSUVEZ, therefore, is in excess of US$1bn.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at

Order by Phone at 888-809-8385 or online at

Get our Free Ebook, "Suppressed Health Secrets"  with  Natural Cures THEY don't want you to know!

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Organic Hemp Extract (CBD) - Full Spectrum high CBD (3300mg) hemp extract eases stiff joints, relieves stress and more!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Load more ...




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.